Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020091068 - FUSION PROTEIN

Publication Number WO/2020/091068
Publication Date 07.05.2020
International Application No. PCT/JP2019/043158
International Filing Date 01.11.2019
IPC
C12N 15/16 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
16Hormones
A61K 38/26 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
26Glucagons
A61K 47/64 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61P 3/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
C07K 14/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C07K 14/575 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
575Hormones
Applicants
  • 味の素株式会社 AJINOMOTO CO., INC. [JP]/[JP]
  • エクスエル-プロテイン ゲーエムベーハー XL-PROTEIN GMBH [DE]/[DE]
Inventors
  • 北原 吉朗 KITAHARA, Yoshiro
  • 岡松 順子 OKAMATSU, Yoriko
  • 平澤 成郎 HIRASAWA, Shigeo
  • 菊池 慶実 KIKUCHI, Yoshimi
  • デシュライン ニコル DAESCHLEIN, Nicole
  • ビンダー ウリ BINDER, Uli
Agents
  • 特許業務法人酒井国際特許事務所 SAKAI INTERNATIONAL PATENT OFFICE
Priority Data
2018-20713402.11.2018JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) FUSION PROTEIN
(FR) PROTÉINE DE FUSION
(JA) 融合タンパク質
Abstract
(EN)
The present invention provides a GLP-1 (1-37) modified product having improved stability. More specifically, the present invention provides a fusion protein or the like including: (a) GLP-1 (1-37) having the amino acid sequence of SEQ ID NO: 1 or a GLP-1 (1-37) variant in which 1-3 amino acid residues in the amino acid sequence of SEQ ID NO: 1 are substituted; and (b) a random coil polypeptide portion having an amino acid sequence formed of at least 50 proline and alanine residues.
(FR)
La présente invention concerne un produit modifié de GLP-1 (1-37) ayant une stabilité améliorée. Plus spécifiquement, la présente invention concerne une protéine de fusion ou analogue comprenant : (A) GLP-1 (1-37) ayant la séquence d'acides aminés de SEQ ID NO : 1 ou une variante de GLP-1 (1-37) dans laquelle 1-3 résidus d'acides aminés dans la séquence d'acides aminés de SEQ ID NO : 1 sont substitués; et (b) une partie polypeptidique d'hélice aléatoire ayant une séquence d'acides aminés formée d'au moins 50 résidus de proline et d'alanine.
(JA)
本発明は、安定性が向上したGLP-1(1-37)改変体を提供する。より具体的には、本発明は、下記(a)ならびに(b): (a)配列番号1のアミノ酸配列からなるGLP-1(1-37)、または配列番号1のアミノ酸配列において1~3個のアミノ酸残基が置換されているGLP-1(1-37)変異体;ならびに (b)少なくとも50個のプロリンおよびアラニン残基からなるアミノ酸配列を含むランダムコイルポリペプチド部分 を含む、融合タンパク質などを提供する。
Latest bibliographic data on file with the International Bureau